What $100/Month Gets You in the GLP-1 Market (2026 Reality Check)

Scroll through GLP-1 telehealth ads and you'll see claims of "GLP-1 for $99/month" or "as low as $95." Some are technically true but misleading. Some are outright promotional gimmicks. A few represent actual monthly costs for specific limited programs. Here's the honest breakdown of what $100/month actually buys in the GLP-1 market in 2026.

The economic reality of $100/month

For a US-based 503A compounding pharmacy operation with licensed providers and platform infrastructure, the unit economics at $100/month look like this:

Cost Component	Minimum Per Patient/Month
API (semaglutide)	$20–30
Pharmacy operations	$25–35
Licensed provider review	$15–20
Platform operations	$15–20
Shipping and packaging	$8–12
Customer acquisition	$20–40 (amortized)
Total minimum cost	$103–157

A sustainable $100/month price point requires either aggressive cost-cutting in one or more categories (usually API quality or clinical oversight), unsustainable loss-leader pricing, or the price doesn't include something (medication, shipping, consultation).

Category 1: Legitimate promotional pricing

Several reputable providers use first-month discount pricing to reduce the barrier to starting:

• MEDVi: $99 first month (regular $179)
• Some Sesame Care providers: Lower introductory consultation fees
• WeightWatchers Med+: $25 first month program fee (medication separate)
• Various providers: Coupon codes and holiday promotions for month 1–2

These are legitimate — you really do pay less for month 1. But understand that ongoing pricing is 1.5–3x higher. If you're evaluating monthly affordability, use the ongoing rate, not the promotional one.

Category 2: "Under $100" with asterisks

Some marketing shows sub-$100 pricing that technically applies but with significant conditions:

• "$29 for your first consultation" — true, but medication costs separately.
• "As low as $75/month" — applies to lowest dose, specific format, or introductory period only.
• "Starting at $95/week" — per-week pricing that multiplies to $380+/month.
• "$99 with code NEWYEAR" — coupon-dependent, expires or is one-time-use.

Read pricing carefully. What you'll actually pay month-over-month matters more than headline numbers.

Category 3: Insurance-covered copays

For commercially insured patients with GLP-1 coverage, brand-name medication copays often land in the $0–100/month range after insurance + manufacturer savings cards:

• Wegovy with commercial insurance + savings card: $0–$25/month for eligible patients.
• Zepbound with commercial insurance + savings card: Similar.
• Ozempic or Mounjaro with T2D indication + savings card: $25/month for eligible patients.

This is the cleanest path to genuinely sub-$100 monthly costs. But it requires coverage, prior authorization, and eligibility for savings programs — not universally accessible.

Category 4: Too good to be true

What legitimate budget access actually looks like

The lowest sustainable ongoing prices for legitimate GLP-1 access:

Option	Monthly Cost	What You Get
Insurance copay (if covered)	$25–100	FDA-approved medication
Yucca Health	$146	Compounded injectable, minimal support
Oral Wegovy 1.5mg	$149	FDA-approved oral (through Aug 2026)
MEDVi (ongoing)	$179	Compounded, injectable + oral
Various promos (month 1)	$99–199	Introductory trial only

The HSA/FSA multiplier

HSA (Health Savings Account) and FSA (Flexible Spending Account) contributions are pre-tax, meaning you're paying for GLP-1 medication with dollars that haven't been taxed at your marginal rate. For most taxpayers, this represents a 25–37% effective discount.

Example: Yucca Health at $146/month paid through HSA:

• Gross cost: $146
• Marginal tax rate: 30% (22% federal + 8% state/FICA typical)
• Effective after-tax cost: ~$102/month

This is how you actually get to "under $100/month" for legitimate compounded GLP-1 medication — through tax advantage, not headline pricing gimmicks.

Manufacturer assistance programs

For uninsured or underinsured patients, manufacturer patient assistance programs can provide free or dramatically discounted medication for eligible patients:

• Novo Nordisk Patient Assistance Program: Free Ozempic for eligible uninsured patients meeting income criteria (~200–400% of federal poverty line).
• Lilly Cares Patient Assistance Program: Similar structure for Mounjaro and Zepbound.
• Application requirements: Documentation of income, insurance status, medical necessity. Not quick, but can produce $0/month cost for qualifying patients.

State and nonprofit resources

• 340B program-covered clinics: Federally qualified health centers can offer deeply discounted medications to qualifying patients.
• NeedyMeds database: Catalogs assistance programs by medication.
• Local health departments: Some offer weight-management programs with medication support.
• Clinical trials: Research studies provide free medication in exchange for participation.

The reality check

If your budget is strictly $100/month, your realistic options in 2026:

1. Insurance coverage path: Best option if you qualify. Copays can be $25 or less.
2. Patient assistance: Novo/Lilly programs for eligible patients.
3. Yucca Health through HSA/FSA: $146 gross → ~$102 effective after-tax.
4. First-month promotional pricing: Temporary access at $99 or less to trial before full pricing kicks in.
5. Delay until 2027 Medicare changes if you're a Medicare beneficiary.

Under-$100/month legitimate ongoing pricing is achievable, but usually through subsidy (insurance, tax advantages, assistance) rather than headline cash prices.

Bottom line

"GLP-1 under $100/month" exists but almost always has asterisks: promotional period, insurance coverage, HSA/FSA subsidy, or patient assistance eligibility. The advertised sub-$100 pricing you see in marketing is usually promotional or misleading. Genuine sustained pricing starts around $146/month for compounded and slightly more for FDA-approved oral Wegovy. Plan for that reality, then explore subsidies and assistance programs to bring your actual cost lower.